Get started
Author

Anna Ropenga

Observed name: A. Ropenga
Institution: BioInvent (Sweden)
ORCID: 0009-0000-6934-1741
Observed ORCID: 0009-0000-6934-1741
OpenAlex ID: A5025722647
Abdominal irradiation increases inflammatory cytokine expression and activates NF-κB in rat ileal muscularis layer
2003 · C. Linard, A. Ropenga, et al. · American Journal of Physiology-Gastrointestinal and Liver Physiology · 98
Use of Reference Gene Expression in Rat Distal Colon after Radiation Exposure: A Caveat
2004 · Anna Ropenga, Alain Chapel, et al. · Radiation Research · 53
Increased prokineticin 2 expression in gut inflammation: role in visceral pain and intestinal ion transport
2011 · Robert P. Watson, Elliot Lilley, et al. · Neurogastroenterology & Motility · 50
Direct Bacterial Killing In Vitro by Recombinant Nod2 Is Compromised by Crohn's Disease-Associated Mutations
2010 · Laurent-Herve Perez, Matt Butler, et al. · PLoS ONE · 23
PDF
Persistence of altered 5‐hydroxytryptamine turnover following hemibody X‐irradiation in the rat distal colon
2004 · A. Ropenga, O. Combes, et al. · International Journal of Radiation Biology · 6
A First-in-Class mAb (BI-1607) Targeting FcγRIIB: Preclinical Data and First-in-Human Studies in Patients with HER2-Positive Advanced Solid Tumors
2025 · Javier Cortés, Araceli Priego, et al. · Clinical Cancer Research · 3
PDF
S1672 TD-8954 Is a Highly Potent and Selective 5-HT4 Receptor Agonist with Potential Utility in Disorders of Reduced Gastrointestinal Motility
2008 · David T. Beattie, Ross G. Vickery, et al. · Gastroenterology · 3
PDF
1024P Initial clinical results of BT-001, an oncolytic virus expressing an anti-CTLA4 mAb, administered as single agent and in combination with pembrolizumab in patients with advanced solid tumors
2024 · S. Champiat, C. Lebbe, et al. · Annals of Oncology · 2
Supplementary Material S1 from A First-in-Class mAb (BI-1607) Targeting FcγRIIB: Preclinical Data and First-in-Human Studies in Patients with HER2-Positive Advanced Solid Tumors
2025 · Javier Cortés, Araceli Priego, et al.
PDF
Supplementary Table S1 from A First-in-Class mAb (BI-1607) Targeting FcγRIIB: Preclinical Data and First-in-Human Studies in Patients with HER2-Positive Advanced Solid Tumors
2025 · Javier Cortés, Araceli Priego, et al.
Supplementary Figure S6 from A First-in-Class mAb (BI-1607) Targeting FcγRIIB: Preclinical Data and First-in-Human Studies in Patients with HER2-Positive Advanced Solid Tumors
2025 · Javier Cortés, Araceli Priego, et al.
PDF
Supplementary Figure S9 from A First-in-Class mAb (BI-1607) Targeting FcγRIIB: Preclinical Data and First-in-Human Studies in Patients with HER2-Positive Advanced Solid Tumors
2025 · Javier Cortés, Araceli Priego, et al.
PDF
Supplementary Figure S3 from A First-in-Class mAb (BI-1607) Targeting FcγRIIB: Preclinical Data and First-in-Human Studies in Patients with HER2-Positive Advanced Solid Tumors
2025 · Javier Cortés, Araceli Priego, et al.
PDF
Supplementary Figure S8 from A First-in-Class mAb (BI-1607) Targeting FcγRIIB: Preclinical Data and First-in-Human Studies in Patients with HER2-Positive Advanced Solid Tumors
2025 · Javier Cortés, Araceli Priego, et al.
PDF
Supplementary Figure S7 from A First-in-Class mAb (BI-1607) Targeting FcγRIIB: Preclinical Data and First-in-Human Studies in Patients with HER2-Positive Advanced Solid Tumors
2025 · Javier Cortés, Araceli Priego, et al.
PDF
Supplementary Figure S2 from A First-in-Class mAb (BI-1607) Targeting FcγRIIB: Preclinical Data and First-in-Human Studies in Patients with HER2-Positive Advanced Solid Tumors
2025 · Javier Cortés, Araceli Priego, et al.
PDF
Supplementary Figure S1 from A First-in-Class mAb (BI-1607) Targeting FcγRIIB: Preclinical Data and First-in-Human Studies in Patients with HER2-Positive Advanced Solid Tumors
2025 · Javier Cortés, Araceli Priego, et al.
PDF
Supplementary Figure S5 from A First-in-Class mAb (BI-1607) Targeting FcγRIIB: Preclinical Data and First-in-Human Studies in Patients with HER2-Positive Advanced Solid Tumors
2025 · Javier Cortés, Araceli Priego, et al.
PDF
Supplementary Figure S4 from A First-in-Class mAb (BI-1607) Targeting FcγRIIB: Preclinical Data and First-in-Human Studies in Patients with HER2-Positive Advanced Solid Tumors
2025 · Javier Cortés, Araceli Priego, et al.
PDF
Supplementary Table S2 from A First-in-Class mAb (BI-1607) Targeting FcγRIIB: Preclinical Data and First-in-Human Studies in Patients with HER2-Positive Advanced Solid Tumors
2025 · Javier Cortés, Araceli Priego, et al.
Data from A First-in-Class mAb (BI-1607) Targeting FcγRIIB: Preclinical Data and First-in-Human Studies in Patients with HER2-Positive Advanced Solid Tumors
2025 · Javier Cortés, Araceli Priego, et al.
955P Updated clinical results of BT-001, an oncolytic virus expressing an anti-CTLA4 mAb, administered in combination with pembrolizumab in patients with advanced solid tumors
2025 · C. Lebbe, R. Bahleda, et al. · Annals of Oncology
PDF
Abstract PO1-18-06: Phase 1/2a Open-label Clinical Trial of BI-1607, an Fc Engineered Monoclonal Antibody to CD32b (FcγRIIB), in Combination with Trastuzumab in Subjects with HER2-positive Advanced Solid Tumors – CONTRAST
2024 · Javier Cortés, Araceli Priego, et al. · Cancer Research
Direct Bacterial Killing In Vitro by Recombinant Nod2 Is Compromised by Crohn's Disease-Associated Mutations
2010 · Laurent–Herve Perez, Matt Butler, et al. · Gastroenterology
PDF
S1770a Direct Bacterial Killing In Vitro by Recombinant NOD2 is Compromised by Crohn's Disease-Associated Mutations
2010 · Laurent-Herve Perez, Matt Butler, et al. · Gastroenterology
Works count: 26
Citation count: 238
H-index: 5
I10-index: 4
Year
Topic
Type